IiSGM

L1: Pharmacological measures for the prevention of acute lung injury after lung resection surgery.

L2: Optimisation of one-lung ventilation

L3: Prevention of postoperative complications after mechanical ventilation in non-cardiothoracic surgery.

Axis 2: Epidemiology of respiratory diseases

L1: Historical evolution of hospital admissions due to respiratory diseases analysis of the CMBD

L2: predictive model of obesity in OSAHS (GENOBIA)

Axis 3: Sleep Respiratory Disturbances

L1: Obesity-Hypoventilation Syndrome

L2: Sleep Disorders and Heart Disease.

Axis 4: Development of new drugs or new indications

L1: Development of biological products for the prevention of COPD exacerbations.

L2: Development of P2X3 receptor inhibitors for cough treatment Gefapixant (MK-7264-042 and 043) and Eliapixant.

L3: Development of antifibrotic medication for IPF

L4: Development of biological medication for eosinophilic asthma

L5: Development of anti-inflammatory drugs for the treatment of bronchiectasis.

Axis 5: Experimental model of lung transplantation

L1: Organ preservation.

Axis 6: Treatment of COPD patients with cardiopathy

L1: Impact of respiratory drugs on cardiac function in COPD patients with low ejection fraction

Axis 7: Monitoring of patients with sleep-disordered breathing and chronic respiratory failure

L1: Mechanical simulation of respiratory therapies and their effect on lung dynamics

Axis 8: Neuroanatomics of the larynx

L1: Laryngeal anatomical variability

L2: Laryngeal reinnervation